These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1493 related articles for article (PubMed ID: 33542329)
1. Estimated seroprevalence of SARS-CoV-2 antibodies among adults in Orange County, California. Bruckner TA; Parker DM; Bartell SM; Vieira VM; Khan S; Noymer A; Drum E; Albala B; Zahn M; Boden-Albala B Sci Rep; 2021 Feb; 11(1):3081. PubMed ID: 33542329 [TBL] [Abstract][Full Text] [Related]
2. Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California. Yamaki J; Peled H; Mathews S; Park D; Firoozi M; Smith K; Nguyen L J Racial Ethn Health Disparities; 2021 Dec; 8(6):1551-1555. PubMed ID: 33230735 [TBL] [Abstract][Full Text] [Related]
3. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic. Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441 [TBL] [Abstract][Full Text] [Related]
4. A Saliva-Based Serological and Behavioral Analysis of SARS-CoV-2 Antibody Prevalence in Howard County, Maryland. Brown AC; Koshute PT; Cowley HP; Robinette MS; Gravelyn SR; Patel SV; Ju EY; Frommer CT; Zambidis AE; Schneider EJ; Zhao MY; Mugo BK; Clarke W; Kruczynski K; Pisanic N; Heaney CD; Colella TA Microbiol Spectr; 2023 Aug; 11(4):e0276522. PubMed ID: 37289070 [TBL] [Abstract][Full Text] [Related]
5. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201 [TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. Mahajan S; Srinivasan R; Redlich CA; Huston SK; Anastasio KM; Cashman L; Massey DS; Dugan A; Witters D; Marlar J; Li SX; Lin Z; Hodge D; Chattopadhyay M; Adams MD; Lee C; Rao LV; Stewart C; Kuppusamy K; Ko AI; Krumholz HM Am J Med; 2021 Apr; 134(4):526-534.e11. PubMed ID: 33130124 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 antibody seroprevalence among firefighters in Orange County, California. Vieira V; Tang IW; Bartell S; Zahn M; Fedoruk MJ Occup Environ Med; 2021 Nov; 78(11):789-792. PubMed ID: 34433659 [TBL] [Abstract][Full Text] [Related]
8. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19). Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP; Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702 [TBL] [Abstract][Full Text] [Related]
9. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis. Bobrovitz N; Arora RK; Cao C; Boucher E; Liu M; Donnici C; Yanes-Lane M; Whelan M; Perlman-Arrow S; Chen J; Rahim H; Ilincic N; Segal M; Duarte N; Van Wyk J; Yan T; Atmaja A; Rocco S; Joseph A; Penny L; Clifton DA; Williamson T; Yansouni CP; Evans TG; Chevrier J; Papenburg J; Cheng MP PLoS One; 2021; 16(6):e0252617. PubMed ID: 34161316 [TBL] [Abstract][Full Text] [Related]
10. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?]. Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F; Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811 [TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441 [TBL] [Abstract][Full Text] [Related]
12. Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020. Kugeler KJ; Podewils LJ; Alden NB; Burket TL; Kawasaki B; Biggerstaff BJ; Biggs HM; Zacks R; Foster MA; Lim T; McDonald E; Tate JE; Herlihy RK; Drobeniuc J; Cortese MM Public Health Rep; 2022; 137(1):128-136. PubMed ID: 34752156 [TBL] [Abstract][Full Text] [Related]